Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists.
Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, Department of Medicine, CHU Liège, University of Liège, B-4000 Liège, Belgium. Electronic address: andre.scheen@chu.ulg.ac.be.
André J
AJ
Scheen
D002319:Cardiovascular System / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives*; D006801:Humans; D054795:Incretins / Q000009:adverse effects*; D008297:Male
D054795:Incretins; D052216:Glucagon-Like Peptide 1